ProShares UltraPro Short QQQ ETF vs 22nd Century Group Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 3587.1× 22nd Century Group Inc's market cap, and ProShares UltraPro Short QQQ ETF is more actively traded (60,436,012 versus 45,625). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and 22nd Century Group Inc for 32 Days on average.
| SQQQ | XXII | |
|---|---|---|
Market Cap | $2.23B | $621.67K |
Volume | 60,436,012 | 45,625 |
Sector | Leveraged / Inverse | Consumer Staples |
52-Week High | $89.43 | $483.00 |
52-Week Low | $31.83 | $0.80 |
Typical Hold Time | 12 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
SQQQ trades at $32.95, up 2.71% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows no traditional financial ratios as it's an inverse leveraged product designed to move opposite the Nasdaq 100. Recent news highlights its role as a hedging tool against tech sector declines, with articles discussing strategic pairing with QQQ positions.
As a 3x leveraged inverse ETF, SQQQ carries significant risk from daily rebalancing and decay. It serves as a tactical tool for bearish Nasdaq 100 views or portfolio hedging, but requires active management. The primary risk remains volatility decay and timing sensitivity in a market where tech stocks have shown long-term growth trends.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →